VYJUVEK Market Report 2026

VYJUVEK Market Overview

• The VYJUVEK market growth in the historic period has been driven by advancements in gene delivery vectors, improved understanding of collagen-related genetic disorders • Market expansion is supported by expansion of gene therapy approvals for dermatology, rising demand for durable rare disease treatments • Growth Driver: Rising Prevalence Of Chronic Diseases Driving Market Growth Due To Increasing Demand For Gene Therapy Treatments • Market Trend: Development of the First-Ever Redosable Gene therapy for dystrophic epidermolysis Bullosa (DEB) • North America was the largest region in 2025.

What Is Covered Under VYJUVEK Market?

Vyjuvek is a topical gene therapy designed to treat dystrophic epidermolysis bullosa (DEB) by delivering functional COL7A1 genes to affected skin cells for sustained collagen production and wound healing. It is used to restore skin integrity and promote healing in individuals with DEB, addressing the genetic root cause of the condition, and is the first redosable gene therapy approved for this rare disease. The main indications of the vyjuvek include epidermolysis bullosa (EB) and dystrophic epidermolysis bullosa (DEB). Epidermolysis Bullosa (EB) is a group of rare genetic disorders that cause fragile skin, leading to blister formation with minimal trauma. It results from mutations affecting proteins that bind the skin layers together, causing the skin to separate. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by several end users, such as adults, pediatrics, and geriatrics.

What Is The VYJUVEK Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of gene therapy approvals for dermatology, rising demand for durable rare disease treatments, growing investments in topical gene delivery technologies, advancements in redosable therapy platforms, increasing focus on patient-centric genetic therapies. Major trends in the forecast period include increasing adoption of topical gene therapies, rising focus on rare genetic skin disorders, growing use of redosable gene therapy platforms, expansion of targeted wound healing solutions, enhanced emphasis on localized gene delivery.

Global VYJUVEK Market Segmentation

1) By Indication: Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa (DEB) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult, Pediatric, Geriatric

What Is The Driver Of The VYJUVEK Market?

The rising prevalence of chronic diseases is expected to propel the growth of the vyjuvek market going forward. Chronic diseases are long-lasting health conditions that typically persist for a year or more, requiring ongoing medical attention and often limiting daily activities. The rising prevalence of chronic diseases is driven by aging populations, unhealthy lifestyle choices, increased urbanization, and greater exposure to environmental risk factors. Vyjuvek helps chronic diseases like dystrophic epidermolysis bullosa by delivering a functional COL7A1 gene through its topical gel formulation, enabling the production of type VII collagen, which strengthens the skin’s structure, promotes wound healing, reduces the frequency and severity of chronic wounds, and improves the overall quality of life for patients managing this debilitating condition. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK are affected by allergies, making it the most commonly reported chronic health condition in 2022, with projections indicating that by 2026, half of Europe's population is expected to experience at least one allergy. Therefore, rising prevalence of chronic diseases is driving the vyjuvek industry.

Key Players In The Global VYJUVEK Market

Major companies operating in the vyjuvek market are Krystal Biotech Inc.

Global VYJUVEK Market Trends and Insights

key companies in the vyjuvek market are focusing on developing innovative products such as the first-ever redosable gene therapy to ensure sustained therapeutic effects, address progressive conditions more effectively, and improve patient outcomes by providing ongoing treatment solutions for genetic disorders like dystrophic epidermolysis bullosa (DEB). The first-ever redosable gene therapy refers to a groundbreaking treatment approach that allows for multiple administrations of a gene therapy to maintain or enhance its therapeutic effects over time. For instance, in May 2023, Krystal Biotech Inc., a US-based biotechnology company, announced the FDA approval of VYJUVEK (beremagene geperpavec-svdt), the first-ever redosable gene therapy, for the treatment of Dystrophic Epidermolysis Bullosa (DEB). This topical gel directly addresses the genetic root cause of DEB by restoring functional copies of the COL7A1 gene, enabling wound healing and sustained functional collagen protein expression. Its approval signifies a transformative milestone, offering the first FDA-approved treatment for DEB that is safe, non-invasive, and can be administered in both clinical and home settings.

What Are Latest Mergers And Acquisitions In The VYJUVEK Market?

In September 2024, Swixx BioPharma AG, a Switzerland-based specialty commercialization company, partnered with Krystal Biotech Inc. to distribute and commercialize VYJUVEK gene therapy across Central and Eastern European markets. This partnership aims to combine Swixx BioPharma’s regional commercial network with Krystal Biotech’s innovative HSV-1 vector-based gene therapy to expand patient access to treatment for dystrophic epidermolysis bullosa. Krystal Biotech Inc. is a US-based biopharmaceutical company specializing in gene therapy solutions for rare diseases.

Regional Insights

North America was the largest region in the vyjuvek market in 202. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the VYJUVEK Market?

The vyjuvek market consists of sales of topical gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the VYJUVEK Market Report 2026?

The vyjuvek market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vyjuvek industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.